Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3580487 Target Snapshot

Sclerostin · SINGLE PROTEIN · Homo sapiens

32Compounds
9Assays
2Approved Drugs
41.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Sclerostin shows approved-linked disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9BQB4. Start with osteoporosis, then reuse UniProt Q9BQB4 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with osteoporosis, then reuse UniProt Q9BQB4 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
osteoporosis

Sclerostin shows approved-linked disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with osteoporosis because it currently carries approved-linked support. Linked drugs include BLOSOZUMAB, ROMOSOZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sclerostin as ChEMBL target CHEMBL3580487, mapped to UniProt Q9BQB4. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sclerostin
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3580487
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9BQB4
Sclerostin
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Sclerostin is the right protein anchor across sources, using UniProt Q9BQB4 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why osteoporosis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSclerostin
UniProt AccessionQ9BQB4
Component TypeProtein
Sequence Length213 aa

Sclerostin

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Sclerostin, mapped to UniProt Q9BQB4. Sequence length is 213 aa.

Mapped IDQ9BQB4
Review nameSclerostin
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Sclerostin shows approved-linked disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
osteoporosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugBLOSOZUMAB
Linked drugROMOSOZUMAB
Approved-linked Approved
postmenopausal osteoporosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugBLOSOZUMAB
Linked drugROMOSOZUMAB
Approved-linked Approved
bone disease
1 linked drug · 1 direct · 1 efficacy
Linked drugROMOSOZUMAB
Late clinical Phase III
osteogenesis imperfecta
2 linked drugs · 2 direct · 2 efficacy
Linked drugROMOSOZUMAB
Linked drugSETRUSUMAB
Clinical signal Phase II
bone fracture
1 linked drug · 1 direct · 1 efficacy
Linked drugROMOSOZUMAB
Clinical signal Phase II
hypophosphatasia
1 linked drug · 1 direct · 1 efficacy
Linked drugSETRUSUMAB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with osteoporosis because it currently carries approved-linked support. Linked drugs include BLOSOZUMAB, ROMOSOZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseosteoporosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
Assay Mix

Activity Type Distribution

IC5012.0
EC5011.0
KD18.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5558704 7.81 Kd 15.4 Preclinical
CHEMBL4448063 7.7 IC50 20.0 Preclinical
CHEMBL4448674 7.7 IC50 20.0 Preclinical
CHEMBL4455231 7.7 IC50 20.0 Preclinical
CHEMBL4459781 7.7 IC50 20.0 Preclinical
CHEMBL4475291 7.7 IC50 20.0 Preclinical
CHEMBL4544777 7.7 IC50 20.0 Preclinical
CHEMBL4546624 7.47 EC50 34.2 Preclinical
CHEMBL2021342 7.42 Kd 37.66 Preclinical
CHEMBL4570369 7.28 EC50 52.7 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
9
5.5
7
6.0
7
6.5
6
7.0
8
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

Assay Landscape

Assay Landscape

9
Total Assays
32
Tested Compounds
1
Assay Types
Binding — 9 assays, 32 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 6 5.6
single protein format 4 15 6.7
assay format 1 11 6.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine